Celyad S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
146.00
3.00
8,523.00
3,540.00
3,115
Cost of Goods Sold (COGS) incl. D&A
886.00
979.00
1,034.00
1,569.00
2,229.00
1,114
Gross Income
886.00
833.00
1,031.00
6,954.00
1,311.00
2,001
SG&A Expense
12,133.00
20,017.00
28,963.00
35,903.00
30,504.00
34,222
EBIT
-
20,214.00
29,582.00
28,949.00
29,193.00
33,219
Unusual Expense
1,158.00
-
-
-
26,273.00
5,786
Non Operating Income/Expense
66.00
3,758.00
92.00
4,033.00
2,874.00
1,021
Interest Expense
426.00
22.00
44.00
109.00
144.00
61
Pretax Income
14,489.00
16,201.00
29,366.00
23,612.00
57,557.00
37,737
Income Tax
-
-
-
6.00
1,162.00
310
Equity in Affiliates
-
252.00
252.00
-
-
-
Consolidated Net Income
14,489.00
16,453.00
29,114.00
23,606.00
56,395.00
37,427
Net Income
14,489.00
16,453.00
29,114.00
23,606.00
56,395.00
37,427
Net Income After Extraordinaries
14,489.00
16,453.00
29,114.00
23,606.00
56,395.00
37,427
Net Income Available to Common
14,489.00
16,453.00
29,114.00
23,606.00
56,395.00
37,427
EPS (Basic)
3.53
2.44
3.43
2.53
5.86
3.36
Basic Shares Outstanding
4,099.20
6,750.40
8,481.60
9,313.60
9,627.60
11,142.20
EPS (Diluted)
3.53
2.44
3.43
2.53
5.86
3.36
Diluted Shares Outstanding
4,099.20
6,750.40
8,481.60
9,313.60
9,627.60
11,142.20
EBITDA
12,133.00
19,350.00
28,549.00
27,433.00
27,479.00
32,105
Other Operating Expense
-
636.00
412.00
-
-
998
Non-Operating Interest Income
48.00
277.00
352.00
1,413.00
927.00
308

About Celyad

View Profile
Address
Axis Business Park
Mont-Saint-Guibert WA 1435
Belgium
Employees -
Website http://www.celyad.com
Updated 07/08/2019
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.